GC Biopharma, Hanmi Pharm strike $475m Fabry disease drug deal with BioMarin
Predicted impact: Medium
$475m Fabry deal shared with Hanmi; already reported in recent days, and size is modest versus revenue.
GC Biopharma녹십자
006280 · KOSPI · ₩006280 · 녹십자
₩130,200▼ ₩1,800 (1.36%)End-of-day · Oct 30, 2026 · End-of-day prices.
GC Biopharma Receives Approval for Hunterase ICV in Japan
Predicted impact: Low
Japanese approval of Hunterase ICV, a new market for a small-scale drug approval.
GC Biopharma's Hunterase ICV Approved as First Domestic Treatment for Neuronopathic Hunter Syndrome
Predicted impact: Low
Domestic approval of Hunterase ICV, already reported in the last 14 days.
GC Biopharma, Hanmi Seal Fabry Drug Deal
Predicted impact: Medium
Up to ₩650B Fabry/BioMarin deal, about 42% of market value, already reported in the last 14 days.
GC Biopharma gains domestic approval for Hunter syndrome treatment; 'expands treatment options'
Predicted impact: Medium
Domestic approval of a new drug; the BioMarin licence worth up to ₩650B is about 33% of revenue, so meaningful.
[BioS] GC Biopharma's Hunterase ICV gets MFDS approval for Hunter syndrome
Predicted impact: Medium
Korean drug approval for a new Hunter syndrome therapy; modest near-term revenue impact expected.
GC녹십자·한미약품, 파브리병 치료제 기술수출
High impactPredicted impact: High
Technology export up to $475M, about 38% of Hanmi Pharm's last year revenue (634.7B won deal).
GC Biopharma and Hanmi Pharm sign ₩634.7B technology export of Fabry disease drug to US's BioMarin, expanding K-pharma's reach
Predicted impact: Medium
₩634.7B license deal, about 38% of revenue, but already reported in earlier items this fortnight.
Hanmi Pharm and GC Biopharma license Fabry disease new drug for up to $475M in technology exports
Predicted impact: Medium
Up to $475M licensing deal, repeating the earlier Fabry drug export news.
GC Biopharma and Hanmi Pharm's jointly developed new drug licensed to US BioMarin
Predicted impact: Medium
Technology export up to $475M; about 640B won deal already reported earlier, roughly 39% of market value.
GC Biopharma and Hanmi transfer technology to US BioMarin for up to ₩650B
High impactPredicted impact: High
Up to ₩650B tech transfer, about 42% of GC Biopharma's market value.
GC Biopharma and Hanmi Pharm export next-generation Fabry disease drug technology
Predicted impact: Medium
Next-gen Fabry technology export; likely the same deal as the ₩640B item.
GC Biopharma and Hanmi Pharm export Fabry disease drug candidate to US firm for ₩640B
High impactPredicted impact: High
₩640B tech export, about 13% of Hanmi's market value and 39% of revenue.
Will GC Biopharma's Administrative Lawsuit Loss Be Overturned? Constitutional Court Holds First Hearing on Constitutional Complaint Against Court Ruling
Predicted impact: Medium
Constitutional Court first hearing on the same vaccine collusion case; the case is already known, so the level is lowered.
GC Biopharma Lost Administrative Suit Despite Acquittal in Criminal Collusion Trial: Key Issues in Constitutional Complaint
Predicted impact: Medium
Administrative suit lost despite criminal acquittal; constitutional complaint pending, with prior coverage lowering the level.
GC Biopharma operating profit up 40% despite lower sales; target price KRW 190,000 maintained
Predicted impact: Low
Same Q3 profit up 40% and KRW 190,000 target already covered in recent items.
IBK Securities: "Green Cross: Q3 revenue declines but operating profit up 40%… target price KRW 190,000"
Predicted impact: Low
Analyst preview of Q3 operating profit up 40% was already reported in recent days.
GC Biopharma Expected to Post 40% Rise in 3Q Operating Profit, Driven by Vaccines and Alyglo Growth [Why Bio]
Predicted impact: Medium
Third-quarter operating profit expected up 40%; meaningful earnings move for a mid-cap.
Green Cross Target Price Plunges to ₩180,000 on Lower Corporate Value - Kiwoom
Predicted impact: Low
Target price cut on lower corporate value; routine broker revision.
Kiwoom Securities Lowers Green Cross Target Price… "COVID Treatment Sales Plunge Year on Year"
Predicted impact: Low
Also known as: GC Biopharma / 녹십자 / 006280 / KRX:006280
Source: KRX statistical information